GMP – Page 97 – Pharma.Tips

Specification change not communicated during deviation investigation – preventing batch rejection and recalls

Strategies to Address Uncommunicated Specification Changes During Deviation Investigations In the complex landscape of pharmaceutical manufacturing, uncommunicated specification changes can jeopardize batch integrity and lead to costly recalls. The lack…

Inadequate vendor qualification during routine supplier audit – how to prevent repeat supplier failures

Addressing Insufficient Vendor Qualification in Routine Supplier Audits to Prevent Future Failures In the pharmaceutical industry, suppliers play a critical role in ensuring the quality and integrity of raw materials.…

Change control documentation gaps during supplier change – risk-based change impact assessment

Tackling Documentation Gaps in Change Control During Supplier Transitions In pharmaceutical manufacturing, maintaining robust change control documentation is critical, particularly when transitioning to a new supplier for raw materials. Gaps…

Vendor change implemented without approval during routine supplier audit – inspection questions regulators ask

Unapproved Vendor Change Detected During Routine Supplier Audit: A Methodical Investigation When a vendor change is implemented without prior approval during a routine supplier audit, it can expose a pharmaceutical…

Supplier change not evaluated during post-approval change review – inspection questions regulators ask

Addressing Supplier Changes Not Evaluated During Post-Approval Reviews In the dynamic landscape of pharmaceutical manufacturing, managing supplier changes is critical to maintaining product integrity and compliance. A supplier change not…

Audit response ineffective during requalification – evidence pack for vendor oversight

Addressing Audit Response Ineffectiveness During Requalification In today’s regulatory landscape, manufacturers must often confront the challenge of ensuring that their audit responses are effective, particularly during the requalification of suppliers.…

Raw material change implemented without assessment during post-approval change review – preventing batch rejection and recalls

Mitigating Risks of Unassessed Raw Material Changes During Post-Approval Reviews In the pharmaceutical manufacturing landscape, the integrity of raw materials forms the backbone of quality assurance and regulatory compliance. A…

Inadequate vendor qualification during supply disruption – inspection questions regulators ask

Understanding Inadequate Vendor Qualification During Supply Disruption: An Investigative Approach In the pharmaceutical manufacturing realm, supply chain disruptions often expose inadequacies in vendor qualification processes. Recent encounters have revealed how…

Tag: GMP

Specification change not communicated during deviation investigation – preventing batch rejection and recalls

Inadequate vendor qualification during routine supplier audit – how to prevent repeat supplier failures

Change control documentation gaps during supplier change – risk-based change impact assessment

Vendor change implemented without approval during routine supplier audit – inspection questions regulators ask

Supplier change not evaluated during post-approval change review – inspection questions regulators ask

Audit response ineffective during requalification – evidence pack for vendor oversight

Raw material change implemented without assessment during post-approval change review – preventing batch rejection and recalls

Inadequate vendor qualification during supply disruption – inspection questions regulators ask

Unapproved material substitution during regulatory inspection – inspection questions regulators ask

Supplier audit findings escalated during regulatory inspection – supplier risk classification strategy

Raw material change implemented without assessment during deviation investigation – CAPA to prevent repeat failures

Critical supplier risk not assessed during supplier onboarding – how to prevent repeat supplier failures